scholarly journals Hyperplastic and atrophic changes in the genital tract of a female cat following repeated treatment with deslorelin acetate – a case report

2021 ◽  
Vol 90 (2) ◽  
pp. 207-210
Author(s):  
Gabriele Marino ◽  
Cecilia Vullo ◽  
Stefania Di Giorgio ◽  
Antonina Zanghì ◽  
Giuseppe Catone ◽  
...  
Keyword(s):  
Case Report ◽  
Genital Tract ◽  
Ovarian Function ◽  
Term Treatment ◽  
Repeated Treatment ◽  
Target Organs ◽  
Long Term Treatment ◽  
Adult Cats ◽  
Periovulatory Follicles

This study aimed to investigate the morphological patterns of the genital tract after long-term treatment of deslorelin acetate in a female cat, a gonadotropin-releasing hormone agonist currently used in adult cats to obtain transient oestrus suppression. A 1-year-old Chartreux female cat was treated with 4.7 mg deslorelin acetate to suppress oestrus manifestations. The treatment was repeated for a total of × 3 every 2 years. After 8 years, the female cat came into oestrus again, but she was no more implanted, and an ovariohysterectomy was performed. Before surgery, an ultrasound examination was performed that showed a normal uterus and the presence of about 5 follicles in ovaries. Concentrations of oestradiol, progesterone, and vaginal smears were compatible with oestrus. During surgery, a very short ovarian pedicle was observed yet neither uterus nor ovaries presented appreciable alterations. At histology, the ovaries presented a juvenile appearance with numerous primordial and periovulatory follicles. The uterus showed marked endometrial hyperplasia with polypoid projection and atrophic myometrium. Based on this case report, deslorelin acetate is a powerful drug able to preserve ovarian function. However, the suppression of gonadotrophin, especially for a long period, has a detrimental atrophic effect on the target organs during treatment and, on the opposite, hyperplastic changes may occur after the restoring of normal cyclicity.

scholarly journals Fresh frozen plasma as a source of plasminogen for ligneous conjunctivitis: Case report and a review of the literature

2021 ◽  
pp. 031-035
Author(s):  
Park Benjamin J ◽  
Camoriano David ◽  
Vital Mark C ◽  
Chévez-Barrios Patricia ◽  
Goosey John D ◽  
...  
Keyword(s):  
Case Report ◽  
Fresh Frozen Plasma ◽  
Term Treatment ◽  
Ligneous Conjunctivitis ◽  
Caucasian Girl ◽  
Long Term Treatment ◽  
Effective Option ◽  
Fresh Frozen ◽  
Frozen Plasma

Purpose: To describe management of a patient with ligneous conjunctivitis secondary to plasminogen deficiency and review the literature on treatment with plasminogen. Design: Interventional case report. Methods: A 6-year-old Caucasian girl developed ligneous conjunctivitis recalcitrant to debridement and treatment with topical cyclosporin A and steroids. The literature was reviewed regarding treatment of ligneous conjunctivitis with plasminogen. Results: The patient was treated with plasminogen containing drops derived from her father’s fresh frozen plasma. The ligneous conjunctivitis resolved, and the patient was managed on these drops for the following 8 years, initiating treatment for flares and tapering according to clinical response. Conclusions: Plasminogen drops concentrated from fresh frozen plasma are a safe and effective option for long-term treatment of ligneous conjunctivitis.

scholarly journals Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report

2011 ◽  
Vol 4 (2) ◽  
pp. 385-391 ◽  
Author(s):  
Alexandra Karadimou ◽  
Magdalini Migou ◽  
Afroditi Economidi ◽  
Alexandros Stratigos ◽  
Christos Kittas ◽  
...  
Keyword(s):  
Case Report ◽  
Leukocytoclastic Vasculitis ◽  
Term Treatment ◽  
Long Term Treatment

Idiopathic Recurrent Catatonia Needs Maintenance Lorazepam: Case Report and Review

2007 ◽  
Vol 41 (7) ◽  
pp. 625-627 ◽  
Author(s):  
Narayana Manjunatha ◽  
Sahoo Saddichha ◽  
Christoday R.-J. Khess
Keyword(s):  
Case Report ◽  
Mood Disorders ◽  
Term Treatment ◽  
Down Regulation ◽  
Gaba A ◽  
Periodic Catatonia ◽  
Long Term Treatment ◽  
History Of ◽  
High Doses

Objectives: Catatonia as a phenomenon has been well described with either a schizophrenic illness, severe mood disorders or periodic catatonia disorder. We aim to report a patient who had recurrent catatonia that responded to and required lorazepam for maintenance. Methods: We describe the case of a 28 year old woman who had a history of recurrent catatonia that was unresponsive to most anti-psychotics, but who responded to high doses of lorazepam and needed long-term lorazepam for maintenance. Results and Conclusion: Our patient met the criteria for a diagnosis of idiopathic catatonic disorder. Response to lorazepam suggests that a certain group of patients may require long-term treatment with lorazepam, especially those who may have down-regulation of GABA-A receptors.

Canadian Case Report of Erythema Nodosum Leprosum Successfully Treated with Prednisone and Thalidomide

2010 ◽  
Vol 14 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Mélissa Saber ◽  
Caroline Bourassa-Fulop ◽  
Danielle Bouffard ◽  
Nathalie Provost
Keyword(s):  
Case Report ◽  
Erythema Nodosum ◽  
Term Treatment ◽  
Response To Treatment ◽  
Cutaneous Lesions ◽  
Erythema Nodosum Leprosum ◽  
Long Term Treatment ◽  
The Face ◽  
Systemic Symptoms

Background: Erythema nodosum leprosum (ENL) is a disease rarely encountered in Canada. It is characterized by multiple remissions and recurrences, often requires long-term treatment, and can result in debilitating sequelae. Objective: To promote rapid recognition and adequate therapy for ENL. Methods: Case report of a 39-year-old man diagnosed with an ENL. The clinical and histopathologic features, treatment provided, and response to treatment are detailed in this article. Results: ENL presented itself as painful cutaneous lesions on the face and limbs, bilateral paresthesia of the fourth and fifth fingers, and systemic symptoms. Prednisone 40 mg daily for a week and then 60 mg daily for another week reduced the lesions by 80% and the pain by 50%. Although prednisone 60 mg daily was continued for one more week and then stopped, thalidomide was started at a dose of 300 mg daily for 4 weeks and then reduced gradually, which led to complete resolution. Conclusion: At the 7½-month follow-up, the patient remained completely asymptomatic.

Sign in / Sign up

Export Citation Format

Share Document